Global Antihemophilic Factor

Antihemophilic Factor Comprehensive Study by Type (Plasma Derived, Plasma Derived/VWF Complex, Recombinant Antihemophilic Factor), Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2028

Antihemophilic Factor Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Antihemophilic Factor Market Scope
Hemophilia is a rare hereditary bleeding condition that, if not properly managed, can result in life-threatening bleeding episodes as well as significant and expensive consequences, especially due to joint injury. One of the most significant medical breakthroughs of the twentieth century was the development of efficient clotting factor replacement treatment for haemophilia patients. The effectiveness of haemophilia care within specialised comprehensive care centres, advances in factor replacement therapies, the benefits of prophylaxis over on-demand replacement therapy, and the role of aggressive management of joint disease to prevent dysfunction have all been observed over the last three decades of haemophilia care experience. The prevalence of haemophilia is increasing as a result of the rising diagnosis rate, which is likely to fuel the expansion of the antihemophilic factor market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledTakeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (United States), Bayer AG (Germany), Octapharma USA Inc. (United States), Novo Nordisk A/S (Denmark), CSL Behring (United States) and Genzyme Corporation (United States)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Antihemophilic Factor market throughout the predicted period.

Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (United States), Bayer AG (Germany), Octapharma USA Inc. (United States), Novo Nordisk A/S (Denmark), CSL Behring (United States) and Genzyme Corporation (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Antihemophilic Factor market by Type and Region with country level break-up.

On the basis of geography, the market of Antihemophilic Factor has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies

On 2nd December 2020 - Takeda Launched Mypkfit Software for Adynovate [Antihemophilic Factor (Recombinant), Pegylated] to Further Enable Hemophilia a Personalized Care. The myPKFiT for ADYNOVATE Programme Provides a More Efficient Way to Calculating PK Curves, Which Is a Critical Metric for Determining Drug Exposure Over Time. and On 30th August 2018 - Bayer Received United States FDA Approval for its Jivi, New Hemophilia a Treatment with Step-Wise Prophylaxis Dosing Regimen. Developed for the Routine Prophylactic Treatment of Hemophilia a In Previously Treated Adults and Adolescents 12 Years of Age or Older.


Influencing Trend:
Rising Geriatric Population

Market Growth Drivers:
Prevalence of Hemophilia Cases and High Investment in Healthcare R&D

Challenges:
Market Penetration Across New Regions and Lack of Expertise

Restraints:
High Initial Investment

Opportunities:
Growth Across Healthcare Infrastructure Across Emerging Regions

Key Target Audience
Antihemophilic Factor Solution Developers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Plasma Derived
  • Plasma Derived/VWF Complex
  • Recombinant Antihemophilic Factor
By Distribution
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Hemophilia Cases
      • 3.2.2. High Investment in Healthcare R&D
    • 3.3. Market Challenges
      • 3.3.1. Market Penetration Across New Regions
      • 3.3.2. Lack of Expertise
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antihemophilic Factor, by Type, Distribution, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antihemophilic Factor (Value)
      • 5.2.1. Global Antihemophilic Factor by: Type (Value)
        • 5.2.1.1. Plasma Derived
        • 5.2.1.2. Plasma Derived/VWF Complex
        • 5.2.1.3. Recombinant Antihemophilic Factor
      • 5.2.2. Global Antihemophilic Factor by: Distribution (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Antihemophilic Factor by: End User (Value)
        • 5.2.3.1. Pediatric
        • 5.2.3.2. Adult
        • 5.2.3.3. Geriatric
      • 5.2.4. Global Antihemophilic Factor Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antihemophilic Factor: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma USA Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk A/S (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CSL Behring (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genzyme Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Antihemophilic Factor Sale, by Type, Distribution, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antihemophilic Factor (Value)
      • 7.2.1. Global Antihemophilic Factor by: Type (Value)
        • 7.2.1.1. Plasma Derived
        • 7.2.1.2. Plasma Derived/VWF Complex
        • 7.2.1.3. Recombinant Antihemophilic Factor
      • 7.2.2. Global Antihemophilic Factor by: Distribution (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Antihemophilic Factor by: End User (Value)
        • 7.2.3.1. Pediatric
        • 7.2.3.2. Adult
        • 7.2.3.3. Geriatric
      • 7.2.4. Global Antihemophilic Factor Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antihemophilic Factor: by Type(USD Million)
  • Table 2. Antihemophilic Factor Plasma Derived , by Region USD Million (2017-2022)
  • Table 3. Antihemophilic Factor Plasma Derived/VWF Complex , by Region USD Million (2017-2022)
  • Table 4. Antihemophilic Factor Recombinant Antihemophilic Factor , by Region USD Million (2017-2022)
  • Table 5. Antihemophilic Factor: by Distribution(USD Million)
  • Table 6. Antihemophilic Factor Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 7. Antihemophilic Factor Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 8. Antihemophilic Factor Online Pharmacies , by Region USD Million (2017-2022)
  • Table 9. Antihemophilic Factor: by End User(USD Million)
  • Table 10. Antihemophilic Factor Pediatric , by Region USD Million (2017-2022)
  • Table 11. Antihemophilic Factor Adult , by Region USD Million (2017-2022)
  • Table 12. Antihemophilic Factor Geriatric , by Region USD Million (2017-2022)
  • Table 13. South America Antihemophilic Factor, by Country USD Million (2017-2022)
  • Table 14. South America Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 15. South America Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 16. South America Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 17. Brazil Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 18. Brazil Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 19. Brazil Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 20. Argentina Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 21. Argentina Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 22. Argentina Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 23. Rest of South America Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 24. Rest of South America Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 25. Rest of South America Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 26. Asia Pacific Antihemophilic Factor, by Country USD Million (2017-2022)
  • Table 27. Asia Pacific Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 28. Asia Pacific Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 29. Asia Pacific Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 30. China Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 31. China Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 32. China Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 33. Japan Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 34. Japan Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 35. Japan Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 36. India Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 37. India Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 38. India Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 39. South Korea Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 40. South Korea Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 41. South Korea Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 42. Taiwan Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 43. Taiwan Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 44. Taiwan Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 45. Australia Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 46. Australia Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 47. Australia Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 51. Europe Antihemophilic Factor, by Country USD Million (2017-2022)
  • Table 52. Europe Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 53. Europe Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 54. Europe Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 55. Germany Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 56. Germany Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 57. Germany Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 58. France Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 59. France Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 60. France Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 61. Italy Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 62. Italy Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 63. Italy Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 64. United Kingdom Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 65. United Kingdom Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 66. United Kingdom Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 67. Netherlands Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 68. Netherlands Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 69. Netherlands Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 70. Rest of Europe Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 71. Rest of Europe Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 72. Rest of Europe Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 73. MEA Antihemophilic Factor, by Country USD Million (2017-2022)
  • Table 74. MEA Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 75. MEA Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 76. MEA Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 77. Middle East Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 78. Middle East Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 79. Middle East Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 80. Africa Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 81. Africa Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 82. Africa Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 83. North America Antihemophilic Factor, by Country USD Million (2017-2022)
  • Table 84. North America Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 85. North America Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 86. North America Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 87. United States Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 88. United States Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 89. United States Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 90. Canada Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 91. Canada Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 92. Canada Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 93. Mexico Antihemophilic Factor, by Type USD Million (2017-2022)
  • Table 94. Mexico Antihemophilic Factor, by Distribution USD Million (2017-2022)
  • Table 95. Mexico Antihemophilic Factor, by End User USD Million (2017-2022)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Antihemophilic Factor: by Type(USD Million)
  • Table 104. Antihemophilic Factor Plasma Derived , by Region USD Million (2023-2028)
  • Table 105. Antihemophilic Factor Plasma Derived/VWF Complex , by Region USD Million (2023-2028)
  • Table 106. Antihemophilic Factor Recombinant Antihemophilic Factor , by Region USD Million (2023-2028)
  • Table 107. Antihemophilic Factor: by Distribution(USD Million)
  • Table 108. Antihemophilic Factor Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 109. Antihemophilic Factor Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 110. Antihemophilic Factor Online Pharmacies , by Region USD Million (2023-2028)
  • Table 111. Antihemophilic Factor: by End User(USD Million)
  • Table 112. Antihemophilic Factor Pediatric , by Region USD Million (2023-2028)
  • Table 113. Antihemophilic Factor Adult , by Region USD Million (2023-2028)
  • Table 114. Antihemophilic Factor Geriatric , by Region USD Million (2023-2028)
  • Table 115. South America Antihemophilic Factor, by Country USD Million (2023-2028)
  • Table 116. South America Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 117. South America Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 118. South America Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 119. Brazil Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 120. Brazil Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 121. Brazil Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 122. Argentina Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 123. Argentina Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 124. Argentina Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 125. Rest of South America Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 126. Rest of South America Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 127. Rest of South America Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 128. Asia Pacific Antihemophilic Factor, by Country USD Million (2023-2028)
  • Table 129. Asia Pacific Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 130. Asia Pacific Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 131. Asia Pacific Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 132. China Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 133. China Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 134. China Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 135. Japan Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 136. Japan Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 137. Japan Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 138. India Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 139. India Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 140. India Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 141. South Korea Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 142. South Korea Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 143. South Korea Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 144. Taiwan Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 145. Taiwan Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 146. Taiwan Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 147. Australia Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 148. Australia Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 149. Australia Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 150. Rest of Asia-Pacific Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 151. Rest of Asia-Pacific Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 152. Rest of Asia-Pacific Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 153. Europe Antihemophilic Factor, by Country USD Million (2023-2028)
  • Table 154. Europe Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 155. Europe Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 156. Europe Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 157. Germany Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 158. Germany Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 159. Germany Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 160. France Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 161. France Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 162. France Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 163. Italy Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 164. Italy Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 165. Italy Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 166. United Kingdom Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 167. United Kingdom Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 168. United Kingdom Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 169. Netherlands Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 170. Netherlands Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 171. Netherlands Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 172. Rest of Europe Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 173. Rest of Europe Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 174. Rest of Europe Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 175. MEA Antihemophilic Factor, by Country USD Million (2023-2028)
  • Table 176. MEA Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 177. MEA Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 178. MEA Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 179. Middle East Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 180. Middle East Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 181. Middle East Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 182. Africa Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 183. Africa Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 184. Africa Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 185. North America Antihemophilic Factor, by Country USD Million (2023-2028)
  • Table 186. North America Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 187. North America Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 188. North America Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 189. United States Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 190. United States Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 191. United States Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 192. Canada Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 193. Canada Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 194. Canada Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 195. Mexico Antihemophilic Factor, by Type USD Million (2023-2028)
  • Table 196. Mexico Antihemophilic Factor, by Distribution USD Million (2023-2028)
  • Table 197. Mexico Antihemophilic Factor, by End User USD Million (2023-2028)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antihemophilic Factor: by Type USD Million (2017-2022)
  • Figure 5. Global Antihemophilic Factor: by Distribution USD Million (2017-2022)
  • Figure 6. Global Antihemophilic Factor: by End User USD Million (2017-2022)
  • Figure 7. South America Antihemophilic Factor Share (%), by Country
  • Figure 8. Asia Pacific Antihemophilic Factor Share (%), by Country
  • Figure 9. Europe Antihemophilic Factor Share (%), by Country
  • Figure 10. MEA Antihemophilic Factor Share (%), by Country
  • Figure 11. North America Antihemophilic Factor Share (%), by Country
  • Figure 12. Global Antihemophilic Factor share by Players 2022 (%)
  • Figure 13. Global Antihemophilic Factor share by Players (Top 3) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 16. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2022
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 21. Octapharma USA Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Octapharma USA Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 24. Novo Nordisk A/S (Denmark) Revenue: by Geography 2022
  • Figure 25. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 26. CSL Behring (United States) Revenue: by Geography 2022
  • Figure 27. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Genzyme Corporation (United States) Revenue: by Geography 2022
  • Figure 29. Global Antihemophilic Factor: by Type USD Million (2023-2028)
  • Figure 30. Global Antihemophilic Factor: by Distribution USD Million (2023-2028)
  • Figure 31. Global Antihemophilic Factor: by End User USD Million (2023-2028)
  • Figure 32. South America Antihemophilic Factor Share (%), by Country
  • Figure 33. Asia Pacific Antihemophilic Factor Share (%), by Country
  • Figure 34. Europe Antihemophilic Factor Share (%), by Country
  • Figure 35. MEA Antihemophilic Factor Share (%), by Country
  • Figure 36. North America Antihemophilic Factor Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Takeda Pharmaceutical Company Limited (Japan)
  • Pfizer Inc. (United States)
  • Bayer AG (Germany)
  • Octapharma USA Inc. (United States)
  • Novo Nordisk A/S (Denmark)
  • CSL Behring (United States)
  • Genzyme Corporation (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 240 Pages 51 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antihemophilic Factor Quantitative research analysis
Global Antihemophilic Factor Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Antihemophilic Factor Market are by type [Plasma Derived, Plasma Derived/VWF Complex and Recombinant Antihemophilic Factor], by end use application [].
The Antihemophilic Factor Market is gaining popularity and expected to see strong valuation by 2028.
  • Prevalence of Hemophilia Cases
  • High Investment in Healthcare R&D

Know More About Global Antihemophilic Factor Report?

Have a Query? Click Here

Other Related Reports

Sicca Syndrome Drug Comprehensive Study by Type (BMS-986142, Belimumab, Coversin, Filgotinib, LY-3090106, Others), Application (Hospital, Clinic, Others), Sales Channels (Online Sales Channel {Compan...
$ 3750
Hematological Malignancies Comprehensive Study by Type (Leukemia, Lymphoma, Myeloma), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Ph...
$ 3650
Behavioral Therapy Comprehensive Study by Type (Cognitive behavioral therapy, Dialectical Behavior Therapy, Cognitive behavioral play therapy, System desensitization, Aversion therapy, Implosion ther...
$ 3750
Gene Therapy Comprehensive Study by Type (Somatic Cell Gene Therapy, Germ Cell Gene Therapy), Application (Neurological Disorders, Rare Diseases, Oncological Disorders, Cardiovascular Diseases, Infec...
$ 3450
Gallbladder Cancer Treatment Comprehensive Study by Type (Gemcitabine, Fluorouracil, Cisplatin, Oxaliplatin, Others (Binimetinib)), End User (Hospitals and Specialty Clinics, Cancer Research and Trea...
$ 3450
Intensive Anti-Aging Treatment Comprehensive Study by Type (Anti-Wrinkle Cream, Anti-stretch Mark Cream, UV absorber, Other), Distribution Channel (Retail Pharmacies, Online Pharmacies, Drug Store) P...
$ 3500